Načítá se...
Rosiglitazone inhibits K(v)4.3 potassium channels by open-channel block and acceleration of closed-state inactivation
BACKGROUND AND PURPOSE: Rosiglitazone is a widely used oral hypoglycaemic agent, which improves insulin resistance in type 2 diabetes. Chronic rosiglitazone treatment is associated with a number of adverse cardiac events. The present study was designed to characterize the effects of rosiglitazone on...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3101614/ https://ncbi.nlm.nih.gov/pubmed/21232039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01210.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|